Azéma Delphine, Duranton Flore, Argilés Àngel, Rial-Sebbag Emmanuelle
Laboratoire CERPOP, équipe BIOETHICS, UMR 1295, Centre d'Epidémiologie et de Recherche en santé des POPulations, Toulouse, France.
RD Néphrologie SAS, Montpellier, France.
Proteomics. 2025 Jun;25(11-12):e202400176. doi: 10.1002/pmic.202400176. Epub 2025 Apr 2.
This article explores the ethical and societal issues in developing personalised medicine (PM) as part of the KidneySign project, which aims to mobilise translational big data to validate a proteomic signature of renal fibrosis with prognostic value. This research offers hope for improved management of chronic kidney disease, including diagnosis and treatment. This article examines how the human and social sciences can be mobilised within a biomedical research project to identify and prevent concomitant ethical, legal and social issues. This point of view defends a multidisciplinary approach to PM and artificial intelligence in medicine. Presenting theoretical and methodological contributions of social sciences in the case of KidneySign offers an opportunity to better understand the integration of these disciplines in biomedical research. It allows us to question the study protocol itself and to frame it through legal obligations, as well as potential legal consequences and challenges. Moreover, sociological assessments help identify key points and highlight the limits of the technophilic fantasy in the representations of patients and health professionals. The introduction of new technologies into medical research and practice requires special attention to ethics.
本文探讨了作为“肾脏信号”（KidneySign）项目一部分的个性化医疗（PM）发展过程中的伦理和社会问题。该项目旨在调动转化大数据，以验证具有预后价值的肾纤维化蛋白质组学特征。这项研究为改善慢性肾脏病的管理（包括诊断和治疗）带来了希望。本文考察了如何在生物医学研究项目中调动人文和社会科学，以识别和预防随之而来的伦理、法律和社会问题。这一观点捍卫了医学中个性化医疗和人工智能的多学科方法。介绍社会科学在“肾脏信号”案例中的理论和方法贡献，为更好地理解这些学科在生物医学研究中的整合提供了契机。这使我们能够质疑研究方案本身，并通过法律义务以及潜在的法律后果和挑战来对其进行界定。此外，社会学评估有助于确定关键点，并突出患者和卫生专业人员观念中技术偏好幻想的局限性。将新技术引入医学研究和实践需要特别关注伦理问题。
